- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05621772
Meridian Activation Remedy System for Parkinson's Disease (MARS-PD)
November 29, 2023 updated by: HoRyong Yoo, Korea Health Industry Development Institute
MARS-PD: Meridian Activation Remedy System for Parkinson's Disease - A Single-center, Rater-blinded, Parallel Randomized Controlled Trial
In this study, the investigators aim to evaluate the clinical efficacy and cost-effectiveness of MARS-PD.
Conventional, usual care will be used as the comparator because this trial aims to assess the add-on effect of MARS-PD.
The investigators hypothesize that the complex therapy will relieve motor and nonmotor symptoms, improve gait performance, and enhance neuroplasticity in PD patients, and will be safe and cost-effective.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
This study is a randomized controlled trial conducted at a single center with raters blinded to the intervention.
We will look at the clinical effect of MARS-PD, consisting of 16 interventions over an 8-week period, in 88 individuals with Parkinson's disease.
Patients will be assigned to either the experimental (n=44) or control (n=44) groups at random. he experimental group will receive the MARS intervention, while the control group will receive usual care only.
The treatment duration is 8 weeks, followed by a 12-week follow-up.
The primary outcome is the change in MDS-UPDRS Part III (Movement Disorder Society Unified Parkinson's Disease Rating Scale Part III) score from baseline to 8 weeks.
Secondary outcomes include assessments such as MDS-UPDRS, International Physical Activity Questionnaire Short Form, Parkinson Self Questionnaire, Parkinson's Disease Sleep Scale, Timed Up and Go test, GAITRite metrics, Functional Near-Infrared Spectroscopy measurements, smart band results, gut microbiome composition and diversity, and iris connective tissue texture.
Study Type
Interventional
Enrollment (Estimated)
88
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Ho Ryong Yoo, Prof. Dr.
- Phone Number: +82-42-470-9131
- Email: hryoo@dju.kr
Study Contact Backup
- Name: Miso S. Park, Prof. Dr.
- Phone Number: +82-42-470-9541
- Email: miso.sophia.park@gmail.com
Study Locations
-
-
-
Daejeon, Korea, Republic of, 35235
- Recruiting
- Clinical Trial Center, Daejeon Korean Medicine Hospital of Daejeon University
-
Contact:
- Miso S. Park, Prof. Dr.
- Phone Number: +82-42-470-9541
- Email: miso.sophia.park@gmail.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
45 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- 45 to 75 years of age
- Patients with PD, diagnosed according to the United Kingdom Parkinson's Diseases Society Brain Bank Criteria
- Hoehn and Yahr scale stage I to III
- Patients who have voluntarily decided to participate in the clinical study and signed the informed consent form
Exclusion Criteria:
- Clinically unstable patients (e.g., elevated aspartate transaminase (AST) or alanine aminotransferase (ALT) more than three-fold the upper limit of normal in the research institute's laboratory, heart failure, respiratory failure, etc.)
- Patients who are planning to undergo deep brain stimulation within the study period
- Pregnant or lactating women
- Patients with MMSE-K (Mini-Mental State Exam) score of 18 or less
- If there has been a change in the dosage of antiparkinsonian drugs (e.g., L-dopa, COMT (catechol-O-methyltransferase) inhibitor, Dopamine agonist, MAO-B (monoamine oxidase B) inhibitor, etc.) according to a doctor's prescription within the last 4 weeks prior to enrollment
- Patients who are receiving manual therapy, exercise therapy, or rehabilitation therapy for Parkinson's disease according to a doctor's prescription within the last 4 weeks prior to enrollment, or are planning to receive such therapy within the study period
- Patients who are not suitable for participation in this clinical study according to the judgment of the researcher
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Experimental group (Meridian Activation Remedy System for Parkinson's Disease)
Meridian Activation Remedy System for Parkinson's Disease (MARS-PD) treatment (16 times/8 weeks total, 2 times/week)
|
MARS-PD is a complex therapy developed by researchers to enhance the synergistic effects of acupuncture and exercise.
|
No Intervention: Control group (Usual Care)
Usual care (all participants will be allowed to continue their prescribed medication and treatment (except Korean Medicine therapy), and they will not receive any additional treatment or therapy in the research institute), and lifestyle advice (all participants will receive a smart band and application-based guidance about their lifestyle)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Movement Disorder Society Unified Parkinson's Disease Rating Scale Part Ⅲ
Time Frame: Change from baseline MDS-UPDRS Part Ⅲ score at 8 weeks
|
MDS-UPDRS Part Ⅲ (maximum: 132, minimum: 0; higher scores mean a worse outcome)
|
Change from baseline MDS-UPDRS Part Ⅲ score at 8 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Movement Disorder Society Unified Parkinson's Disease Rating Scale Part Ⅲ
Time Frame: Change from baseline MDS-UPDRS Part Ⅲ score at 4 and 12 weeks
|
MDS-UPDRS Part Ⅲ
|
Change from baseline MDS-UPDRS Part Ⅲ score at 4 and 12 weeks
|
International Physical Activity Questionnaire Short Form
Time Frame: Change from baseline IPAQ score at 4, 8 and 12 weeks
|
IPAQ
|
Change from baseline IPAQ score at 4, 8 and 12 weeks
|
Parkinson Self Questionnaire
Time Frame: Change from baseline Parkinson Self Questionnaire results at 4, 8 and 12 weeks
|
Parkinson Self Questionnaire, developed by researchers
|
Change from baseline Parkinson Self Questionnaire results at 4, 8 and 12 weeks
|
Parkinson's disease Sleep Scale
Time Frame: Change from baseline PDSS score at 4, 8 and 12 weeks
|
PDSS
|
Change from baseline PDSS score at 4, 8 and 12 weeks
|
Timed up and go test
Time Frame: Change from baseline TUG time in seconds at 8 and 12 weeks
|
TUG
|
Change from baseline TUG time in seconds at 8 and 12 weeks
|
GAITRite Electronic Walkway Platinum
Time Frame: Change from baseline GAITRite parameters at 8 and 12 weeks
|
GAITRite
|
Change from baseline GAITRite parameters at 8 and 12 weeks
|
Functional near-infrared spectroscopy
Time Frame: Change from baseline fNIRS results at 8 and 12 weeks
|
fNIRS
|
Change from baseline fNIRS results at 8 and 12 weeks
|
Smart band outcomes
Time Frame: Change from baseline daily steps at 4, 8 and 12 weeks
|
Number of steps per day
|
Change from baseline daily steps at 4, 8 and 12 weeks
|
Iris imaging 1
Time Frame: Iris connective tissue texture, baseline
|
Visible light image
|
Iris connective tissue texture, baseline
|
Iris imaging 2
Time Frame: Iris connective tissue density, baseline
|
Infrared image
|
Iris connective tissue density, baseline
|
Movement Disorder Society Unified Parkinson's Disease Rating Scale
Time Frame: Change from baseline MDS-UPDRS score at 4, 8 and 12 weeks
|
MDS-UPDRS
|
Change from baseline MDS-UPDRS score at 4, 8 and 12 weeks
|
Gut microbiome test
Time Frame: Change from baseline gut microbiome analysis results at 8 weeks
|
Gut microbiome diversity and composition, fecal samples
|
Change from baseline gut microbiome analysis results at 8 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Ho Ryong Yoo, Prof. Dr., Daejeon University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
April 8, 2022
Primary Completion (Estimated)
September 30, 2024
Study Completion (Estimated)
December 31, 2024
Study Registration Dates
First Submitted
November 4, 2022
First Submitted That Met QC Criteria
November 10, 2022
First Posted (Actual)
November 18, 2022
Study Record Updates
Last Update Posted (Estimated)
December 4, 2023
Last Update Submitted That Met QC Criteria
November 29, 2023
Last Verified
November 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- DJ_PD_21_02
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Parkinson Disease
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedParkinson Disease 6, Early-Onset | Parkinson Disease (Autosomal Recessive, Early Onset) 7, Human | Parkinson Disease Autosomal Recessive, Early Onset | Parkinson Disease, Autosomal Recessive Early-Onset, Digenic, Pink1/Dj1United States
-
ProgenaBiomeRecruitingParkinson Disease | Parkinsons Disease With Dementia | Parkinson-Dementia Syndrome | Parkinson Disease 2 | Parkinson Disease 3 | Parkinson Disease 4United States
-
King's College LondonGlaxoSmithKlineCompletedParkinson Disease | Idiopathic Parkinson Disease | Parkinson Disease, PARK8United Kingdom
-
Ohio State UniversityCompletedParkinson's Disease | Parkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease | Parkinson Disease, Idiopathic | Parkinson's Disease, IdiopathicUnited States
-
National Yang Ming UniversityUnknownEarly Onset Parkinson Disease | Early Stage Parkinson Disease
-
Michele Tagliati, MDRecruitingREM Sleep Behavior Disorder | Symptomatic Parkinson Disease | Pre-motor Parkinson DiseaseUnited States
-
Cedars-Sinai Medical CenterEnrolling by invitationREM Sleep Behavior Disorder | Symptomatic Parkinson Disease | Pre-motor Parkinson DiseaseUnited States
-
Mahatma Gandhi Institute of Medical SciencesCompletedStroke, Parkinson' s Disease, Neurological Impairments, Tele-rehabilitationIndia
-
Merck Sharp & Dohme LLCCompletedParkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease
-
University of DeustoCompletedPARKINSON DISEASE (Disorder)Spain
Clinical Trials on Meridian Activation Remedy System for Parkinson's Disease (MARS-PD)
-
Stony Brook UniversityParkinson's Disease FoundationRecruitingParkinson DiseaseUnited States
-
MedtronicNeuroCompletedParkinson DiseaseBrazil, China
-
Instituto Materno Infantil Prof. Fernando FigueiraCompleted